News

Breaking news coverage from cryptocurrency world about key figures, exchanges, startups, investment, applications, regulation and more.

By October 29th, 2020
Market NewsNews

GILD Stock Dips by 2.15%, Despite Reporting Profitable Q3 Earnings

By October 29th, 2020

Gilead Sciences Inc, the American biopharmaceutical company behind the only approved drug for the treatment of COVID-19 known as Remdesivir (or Veklury) has released its third-quarter earnings in which the company posted better than expected earnings. Per the figures posted, GILD reported product sales of $6.5 billion, an 18% increment year-over-year.